August 2026– date –
-
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib) as First Broad RAS-Targeted Medicine for Metastatic Pancreatic Cancer
MarketScreener USA Overview Revolution Medicines announced that its RASONQUE™ (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer, has received U.S. FDA approval. RASONQUE had previously been granted Br... -
U.S. FDA Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine, Aligned with 2026 Fall Vaccination Guidance
Pfizer USA Overview Pfizer and BioNTech have received U.S. FDA approval for their XFG-adapted COVID-19 vaccine. This approval aligns with the FDA's guidance on the recommended composition for COVID-19 vaccines to be used in the United St... -
AI Firm Noetik Achieves First Milestone in GSK Collaboration, Deploying OCTO-VC Foundational Model’s Inference and Fine-tuning Capabilities for Oncology Drug Discovery
Business Wire Global Overview AI company Noetik has successfully achieved its first short-term milestone in a five-year strategic collaboration and licensing agreement with GSK. This accomplishment was met by Noetik's delivery and deploy... -
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra... -
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
Biopharma M&A Intensifies Driven by Patent Cliffs and Pipeline Enhancement, Evolving Deal Structures with Increased CVRs
Endpoints News Global Overview Biopharma M&A activity is rapidly intensifying, spurred by the pressure of patent expirations and the necessity to fill pipeline gaps. Companies are accelerating acquisitions to secure new therapies and... -
Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech for Accelerated Custom Luminescent Assay Development
The Scientist Global Overview AI-driven protein design company Monod Bio has entered into a non-exclusive licensing agreement with SignalChem Biotech, enabling the integration of Monod Bio's LuxSit de novo luciferase technology and NovoB... -
Biohaven Secures Global Licensing Deal with SK Biopharmaceuticals for Kv7 Ion Channel Platform and Lead Epilepsy Candidate Opakalim, Including $400M Upfront
PR Newswire Global Overview Biohaven and SK Biopharmaceuticals have signed a strategic global licensing and co-development agreement for a novel Kv7 ion channel platform, including its lead candidate Opakalim for focal epilepsy. Under th... -
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for Global Development and Commercialization of Novel GLP-1-Independent Obesity Candidate HM17321
Pharmaceutical Executive Daily Global Overview Hanmi Pharm has signed an exclusive, global licensing agreement with Genentech, a Roche Group member, for the worldwide development, manufacturing, and commercialization of HM17321, a novel ... -
EMA’s CHMP Endorses Marketing Authorization Expansion for Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) for Childhood Obesity in Rare Genetic Disorders (Ages 2+)
Bio-Research.AI Europe Overview Rhythm Pharmaceuticals announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization expansion for IMCIVREE (setmelanoti...
